1. Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials
- Author
-
Manson, JoAnn E, Chlebowski, Rowan T, Stefanick, Marcia L, Aragaki, Aaron K, Rossouw, Jacques E, Prentice, Ross L, Anderson, Garnet, Howard, Barbara V, Thomson, Cynthia A, LaCroix, Andrea Z, Wactawski-Wende, Jean, Jackson, Rebecca D, Limacher, Marian, Margolis, Karen L, Wassertheil-Smoller, Sylvia, Beresford, Shirley A, Cauley, Jane A, Eaton, Charles B, Gass, Margery, Hsia, Judith, Johnson, Karen C, Kooperberg, Charles, Kuller, Lewis H, Lewis, Cora E, Liu, Simin, Martin, Lisa W, Ockene, Judith K, O’Sullivan, Mary Jo, Powell, Lynda H, Simon, Michael S, Van Horn, Linda, Vitolins, Mara Z, and Wallace, Robert B
- Subjects
Biomedical and Clinical Sciences ,Health Services and Systems ,Public Health ,Health Sciences ,Reproductive Medicine ,Clinical Trials and Supportive Activities ,Clinical Research ,Breast Cancer ,Patient Safety ,Estrogen ,Women's Health ,Aging ,Cancer ,6.1 Pharmaceuticals ,Good Health and Well Being ,Aged ,Breast Neoplasms ,Colorectal Neoplasms ,Coronary Disease ,Drug Therapy ,Combination ,Endometrial Neoplasms ,Estrogens ,Estrogens ,Conjugated (USP) ,Female ,Follow-Up Studies ,Hip Fractures ,Hormone Replacement Therapy ,Humans ,Medroxyprogesterone Acetate ,Middle Aged ,Postmenopause ,Pulmonary Embolism ,Quality of Life ,Risk ,Stroke ,Treatment Outcome ,United States ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
ImportanceMenopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention.ObjectiveTo report a comprehensive, integrated overview of findings from the 2 Women's Health Initiative (WHI) hormone therapy trials with extended postintervention follow-up.Design, setting, and participantsA total of 27,347 postmenopausal women aged 50 to 79 years were enrolled at 40 US centers.InterventionsWomen with an intact uterus received conjugated equine estrogens (CEE; 0.625 mg/d) plus medroxyprogesterone acetate (MPA; 2.5 mg/d) (n = 8506) or placebo (n = 8102). Women with prior hysterectomy received CEE alone (0.625 mg/d) (n = 5310) or placebo (n = 5429). The intervention lasted a median of 5.6 years in CEE plus MPA trial and 7.2 years in CEE alone trial with 13 years of cumulative follow-up until September 30, 2010.Main outcomes and measuresPrimary efficacy and safety outcomes were coronary heart disease (CHD) and invasive breast cancer, respectively. A global index also included stroke, pulmonary embolism, colorectal cancer, endometrial cancer, hip fracture, and death.ResultsDuring the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53). Other risks included increased stroke, pulmonary embolism, dementia (in women aged ≥65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms. Most risks and benefits dissipated postintervention, although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48]). The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97). Results for other outcomes were similar to CEE plus MPA. Neither regimen affected all-cause mortality. For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P
- Published
- 2013